Jan 31, 2018 | Featured Insights
Proskauer represented Celgene Corporation in its definitive agreement to acquire Juno Therapeutics, Inc. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities...